Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Experimental Oncology
  • Published:

Characterisation of a LoVo subline resistant to a benzoyl mustard derivative of distamycin A (FCE 24517)

Abstract

Human colon adenocarcinoma cells (LoVo) resistant to the new antitumor agent FCE 24517 [benzoyl-mustard derivative of distamycin A] (LoVo/24517) are resistant to the selecting agent and related molecules as well as to vinblastine, with marginal or no resistance to other antitumour drugs. Treatment with verapamil, tamoxifen, nicergoline or cyclosporin A only partially restores the activity of FCE 24517 against LoVo/24517 cells. Such results suggest that resistance mechanisms possible specific for this class of compounds are operating.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Capolongo, L., Melegaro, G., Broggini, M. et al. Characterisation of a LoVo subline resistant to a benzoyl mustard derivative of distamycin A (FCE 24517). Br J Cancer 68, 916–919 (1993). https://doi.org/10.1038/bjc.1993.454

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/bjc.1993.454

Search

Quick links